Therefore, we validated efficient targeting of the HER-2+ SK-BR-3 and the patients' HER-2+ breast cancer cells (the measurements included are representative for all 10 patients’ biopsies studied) breast cancer cells by the anti-HER-2 × HBsAg. Here, ERBB2 is linked to breast carcinoma.